Fk-506 cytosolic binding protein
CA 2008149 C · Owner: Hung, Hsueh-Yun · Inventors: Mumford, Richard A.; Hung, Hsueh-Yun; Staruch, Marie J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A new homogeneous cytosolic binding (HCB) protein, having a specific binding activity of about 26 µg FK-506 per mg protein and a molecular weight of about 10-12 kilodaltons, reversibly binds the immunosuppressant FK-506 but not cyclosporine A (CSA). The protein is stable to heating at 56 degrees C. for 30 minutes retaining its FK-506 binding affinity, and has the (partial) amino terminal amino acid sequence: H2N-Gly-Val-Gln-Val- Glu-Thr-Ile-Ser-Pro-Gly-Asp-Gly-Arg-Thr-Phe-Pro-Lys- Arg-Gly-Gln-Thr-X-Val-Val-His-Tyr-Thr-Gly-Met-Leu- Glu-Asp-Gly-Lys-Lys-Phe-Asp (wherein X is undefined). The HCB protein is isolated from the -i-, cytosol of mammalian tissues, preferably human neoplastic T-cell …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 19, 1990 and granted August 17, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 19, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 19, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.